Using magnetic resonance imaging (MRI) in infants with older siblings with autism, researchers from around the country were able to correctly predict 80 percent of those infants who would later meet criteria for autism at two years of age.

February 15, 2017 — GE Healthcare announced U.S. Food and Drug Administration (FDA) 510(k) clearance of GSI Xtream on Revolution CT (computed tomography). The company also announced the first series of clinical images and first installations at Duke University Medical Center (USA), Robarts Research Institute (Canada) and The First Affiliated Hospital of Dalian Medical University (China).

February 15, 2017 — Deep learning, also known as artificial intelligence, will increasingly be used in the interpretation of medical images to address many long-standing industry challenges. This will lead to a $300 million market by 2021, according to a new report by Signify Research, an independent supplier of market intelligence and consultancy to the global healthcare information technology industry.

Dicom Systems announced its participation in the HIMSS17 Interoperability Showcase. The redesigned HIMSS (Healthcare Information and Management Systems Society) Interoperability Showcase is a 34,000-sq-ft HIMSS experience that displays, in real time, the exchange and use of data through interoperability profiles and standards with live products currently in the marketplace. As part of public health reporting demonstration, Dicom Systems, along with partner collaborators, will highlight the value of standard-based interoperability.

Researchers from The Ottawa Hospital Breast Health Centre and the Ottawa Integrative Cancer Centre (OICC) have opened the Ottawa site of the Lead-In to the Tomosynthesis Mammographic Imaging Screening Trial (TMIST). The Breast Health Centre is one of three clinical trial sites to launch the Lead-In in Canada. It is expected that shortly this trial will be integrated into a larger U.S./Canada TMIST, managed by the ECOG-ACRIN Cooperative Clinical Trials Group.

The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of the HeartFlow FFRct (fractional flow reserve computed tomography) Analysis to help determine the cause of stable chest pain in patients. Developed by HeartFlow Inc., the HeartFlow FFRct Analysis is the first non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, enabling clinicians to select an appropriate treatment.

Intelerad Medical Systems recently announced that Ransom Memorial Hospital (RMH) has selected Intelerad for its medical imaging platform.

February 14, 2017 — The American Society for Radiation Oncology (ASTRO) recently published an updated clinical guideline that underscores the safety and effectiveness of palliative radiation therapy (RT) for treating painful bone metastases. Based on recent clinical trial data, the guideline recommends optimal RT dosing schedules for pain relief, including options for re-treatment.

February 13, 2017 — Accuray Inc. announced that it has received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its Radixact Treatment Delivery System, Accuray Precision Treatment Planning System and iDMS Data Management System. Together, the treatment delivery system and software solutions enable clinicians to provide efficient, highly precise treatment for a wider range of cancer patients, including those undergoing retreatment. This new Radixact platform is now available in Japan, in certain markets in the European Union, and in the U.S.

FDA, MQSA, mammography record retention and transfer

The U.S. Food and Drug Administration (FDA) has released a new document detailing best practices for retaining patient mammography records in response to ongoing confusion from some mammography facilities, according to the agency.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now